Design and Synthesis of MBP-Fc-Bifunctional Peptide Inhibitor to Improve In Vivo Half-Life and Efficacy
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c00735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Rucha Mahadik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Av, Lawrence, Kansas 66047, United States. Hauptthemen laut MEDLINE: Myelin Basic Protein, Peptides, Encephalomyelitis, Autoimmune, Experimental, Immunoglobulin Fc Fragments. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Multiple Sclerosis (MS) is an autoimmune disease in which the myelin sheath surrounding neurons is degenerate, resulting in physical and cognitive impairment in patients. While current treatments have shown efficacy in reducing symptoms and treating MS, they have also been found to suppress the general immune system. Thus, treated patients are susceptible to opportunistic infections. Bifunctional peptide inhibitors (BPIs) have been designed to selectively target T cells against myelin sheath proteins to promote a tolerogenic response. BPIs are composed of a signal-2 blocking peptide called the LFA-1 alpha blocker left (LABL) peptide and the myelin-derived antigenic peptide linked by a peptide chain. While effective, BPIs have short half-lives and require higher doses to have a therapeutic effect, which could lead to adverse side effects. To mitigate these shortcomings, the BPIs were modified to Fc-BPI by using the Fc region of human IgG1 as a linker between LABL and antigenic peptides. Here, we successfully synthesized MBP-Fc-BPI containing a myelin basic protein (MBP) peptide. The MBP-Fc-BPI has longer half-lives in vitro and in vivo compared to the parent MBP-BPI peptide. The MBP-Fc-BPI had a similar secondary structure and physical stability as the precursor LABL-Fc-ST, indicating that the addition of the MBP antigenic peptide did not alter the conformation of MBP-Fc-BPI. MBP-Fc-BPI significantly suppressed the EAE disease symptoms compared to PBS. MBP-Fc-BPI was more effective in suppressing the EAE than MBP-BPI and LABL-Fc-ST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Av, Lawrence, Kansas 66047, United States.
- Bioengineering Program, The University of Kansas, 1520 W 15th St., Lawrence, Kansas 66045, United States.
ORCID-Profile: Andrea L Villela-Nava, Teruna J Siahaan, Thomas Tolbert
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
- National Institute on Aging
- Pharmaceutical Research and Manufacturers of America Foundation
- National Institute of General Medical Sciences
Zitieren
APA
Mahadik, R., Schwinghamer, K., Villela-Nava, A. L., Siahaan, T. J., & Tolbert, T. (2026). Design and Synthesis of MBP-Fc-Bifunctional Peptide Inhibitor to Improve In Vivo Half-Life and Efficacy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00735
Vancouver
Mahadik R, Schwinghamer K, Villela-Nava AL, Siahaan TJ, Tolbert T. Design and Synthesis of MBP-Fc-Bifunctional Peptide Inhibitor to Improve In Vivo Half-Life and Efficacy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c00735
BibTeX
@article{Mahadik2026,
author = {Mahadik, Rucha and Schwinghamer, Kelly and Villela-Nava, Andrea L and Siahaan, Teruna J and Tolbert, Thomas},
title = {Design and Synthesis of MBP-Fc-Bifunctional Peptide Inhibitor to Improve In Vivo Half-Life and Efficacy},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c00735}
}
EUVIMED